VTGN
NASDAQ
$0.23
VistaGen Therapeutics Inc (VTGN)
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Hold
Target: $1 (+332.71%)
Market Cap
$9.48M
P/B Ratio
0.29
FCF 5Y CAGR
+50.30%
Beta (5Y)
0.92
Price Chart
Valuation
Market Cap$9.48M
P/S7.96
P/B0.29
Profitability
Total Revenue (TTM)$1.27M
Gross Profit (TTM)$1.27M
EBITDA-$72M
Operating Margin-3595%
EPS-$1.89
Growth & Risk
EPS 5Y CAGR-12.57%
Revenue 5Y CAGR+3.10%
FCF 5Y CAGR+50.30%
Beta (5Y)0.92
Sharpe Ratio-0.60